Thumbnail
Access Restriction
Open

Author Neves Cardoso, Pedro ♦ Pinheiro, Ana Fernanda ♦ Meira, Jorge ♦ Pedrosa, Ana Catarina ♦ Falcão, Manuel S. ♦ Pinheiro-Costa, João ♦ Falcão-Reis, Fernando ♦ Carneiro, Ângela M.
Editor Thomas, Biju B.
Source Hindawi
Content type Text
Publisher Hindawi
File Format PDF
Copyright Year ©2017
Language English
Abstract Purpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, p<0.005) between the first and third year. Conclusion. Aflibercept can be useful in the management of refractory neovascular AMD, with a good morphological response. However, in the long-term, BCVA stabilization was not achieved.
ISSN 2090004X
Learning Resource Type Article
Publisher Date 2017-10-19
Rights License This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
e-ISSN 20900058
Journal Journal of Ophthalmology
Volume Number 2017
Page Count 6


Open content in new tab

   Open content in new tab